{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T21:39:03Z","timestamp":1790631543145,"version":"4.1.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T00:00:00Z","timestamp":1777680000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T00:00:00Z","timestamp":1777680000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s40265-026-02321-1","type":"journal-article","created":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T04:00:52Z","timestamp":1777694452000},"page":"1147-1152","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Etripamil: First Approval"],"prefix":"10.1007","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-5649-5651","authenticated-orcid":false,"given":"Michael B.","family":"Brown","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,2]]},"reference":[{"issue":"5","key":"2321_CR1","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1093\/eurheartj\/ehz467","volume":"41","author":"J Brugada","year":"2020","unstructured":"Brugada J, Katritsis DG, Arbelo E, et al. 2019 ESC Guidelines for the management of patients with supraventricular tachycardia: the task force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC): Developed in collaboration with the Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J. 2020;41(5):655\u2013720.","journal-title":"Eur Heart J"},{"issue":"4","key":"2321_CR2","doi-asserted-by":"publisher","first-page":"e136","DOI":"10.1016\/j.hrthm.2015.09.019","volume":"13","author":"RL Page","year":"2016","unstructured":"Page RL, Joglar JA, Caldwell MA, et al. 2015 ACC\/AHA\/HRS guideline for the management of adult patients with supraventricular tachycardia: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Heart Rhythm. 2016;13(4):e136-221.","journal-title":"Heart Rhythm"},{"issue":"11","key":"2321_CR3","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.022648","volume":"11","author":"L Hollanda Oliveira","year":"2022","unstructured":"Hollanda Oliveira L, Viana MDS, Luize CM, et al. Underuse of catheter ablation as first-line therapy for supraventricular tachycardia. J Am Heart Assoc. 2022;11(11):e022648.","journal-title":"J Am Heart Assoc"},{"issue":"18 Suppl 1","key":"2321_CR4","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/S0735-1097(21)01689-2","volume":"77","author":"M Rehorn","year":"2021","unstructured":"Rehorn M, Sacks N, Cyr P, et al. Rates of catheter ablation for paroxysmal supraventricular tachycardia in the United States. JACC. 2021;77(18 Suppl 1):330.","journal-title":"JACC"},{"issue":"10396","key":"2321_CR5","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/S0140-6736(23)00776-6","volume":"402","author":"BS Stambler","year":"2023","unstructured":"Stambler BS, Camm AJ, Alings M, et al. Self-administered intranasal etripamil using a symptom-prompted, repeat-dose regimen for atrioventricular-nodal-dependent supraventricular tachycardia (RAPID): a multicentre, randomised trial. Lancet. 2023;402(10396):118\u201328.","journal-title":"Lancet"},{"issue":"11","key":"2321_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/jcm14113720","volume":"14","author":"M Jha","year":"2025","unstructured":"Jha M, Song D, Kung A, et al. Efficacy and safety of intranasal etripamil for paroxysmal supraventricular tachycardia: meta-analysis of randomized controlled trials. J Clin Med. 2025;14(11):1\u201312.","journal-title":"J Clin Med"},{"key":"2321_CR7","unstructured":"Milestone Pharmaceuticals Inc. Milestone receives FDA approval of CARDAMYST\u2122 (etripamil) as first and only self-administered nasal spray for adults with paroxysmal supraventricular tachycardia (PSVT) [media release]. 12 Dec 2025. https:\/\/milestonepharma.com\/."},{"key":"2321_CR8","unstructured":"Milestone Pharmaceuticals USA Inc. CARDAMYSTTM (etripamil) nasal spray: US prescribing information. 2025. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm. Accessed 08 Apr 2026."},{"key":"2321_CR9","unstructured":"U.S. Food & Drug Administration. FDA approves drug for type of abnormally fast heart rhythm [media release]. 15 Dec 2025. https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-drug-type-abnormally-fast-heart-rhythm."},{"key":"2321_CR10","unstructured":"Milestone P. Milestone Pharmaceuticals reports first quarter 2021 financial results and provides clinical, regulatory, and corporate update [media release]. 17 May 2021. https:\/\/milestonepharma.com\/."},{"key":"2321_CR11","unstructured":"Corxel. CORXEL and LENZ Therapeutics announce positive topline data from China phase 3 presbyopia trial of LNZ100 [media release]. 28 Oct 2024. http:\/\/www.corxelbio.com."},{"key":"2321_CR12","unstructured":"Milestone P. Milestone Pharmaceuticals reports first quarter 2025 financial results and provides regulatory and corporate update [media release]. 15 May 2025. https:\/\/milestonepharma.com\/."},{"issue":"4","key":"2321_CR13","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1002\/cpdd.1383","volume":"13","author":"JE Ip","year":"2024","unstructured":"Ip JE, Wight D, Yue CS, et al. Pharmacokinetics and pharmacodynamics of etripamil, an intranasally administered, fast-acting, nondihydropyridine calcium channel blocker. Clin Pharmacol Drug Dev. 2024;13(4):367\u201379.","journal-title":"Clin Pharmacol Drug Dev."},{"issue":"5","key":"2321_CR14","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.jacc.2018.04.082","volume":"72","author":"BS Stambler","year":"2018","unstructured":"Stambler BS, Dorian P, Sager PT, et al. Etripamil nasal spray for rapid conversion of supraventricular tachycardia to sinus rhythm. J Am Coll Cardiol. 2018;72(5):489\u201397.","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"2321_CR15","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1161\/CIRCEP.122.010915","volume":"15","author":"BS Stambler","year":"2022","unstructured":"Stambler BS, Plat F, Sager PT, et al. First randomized, multicenter, placebo-controlled study of self-administered intranasal etripamil for acute conversion of spontaneous paroxysmal supraventricular tachycardia (NODE-301). Circ Arrhythm Electrophysiol. 2022;15(12):813\u201322.","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"2321_CR16","doi-asserted-by":"crossref","unstructured":"Stambler BS, Camm AJ Sr, Alings M, et al. Self-administered etripamil nasal spray rapidly terminated spontaneous paroxysmal supraventricular tachycardia (PSVT): analysis of open-labeltreatment in the rapid study [abstract no. CE-482905-001]. Heart Rhythm. 2024;21(5S):S32.","DOI":"10.1016\/j.hrthm.2024.03.309"},{"issue":"Suppl 1","key":"2321_CR17","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/euaf085.671","volume":"27","author":"N Li","year":"2025","unstructured":"Li N, Lv Q, Zuo S, et al. Randomized, double-blind, placebo-controlled, efficacy and safety study of etripamil self-administration for the termination of episodes of paroxysmal supraventricular tachycardia in Chinese patients [abstract no. i1150-1]. Europace. 2025;27(Suppl 1):euaf085.671.","journal-title":"Europace"},{"issue":"11","key":"2321_CR18","doi-asserted-by":"publisher","first-page":"2990","DOI":"10.1111\/jce.70086","volume":"36","author":"JE Ip","year":"2025","unstructured":"Ip JE, Coutu B, Ip JH, et al. Etripamil nasal spray for recurrent paroxysmal supraventricular tachycardia conversion: results from the NODE-303 open-label study. J Cardiovasc Electrophysiol. 2025;36(11):2990\u20133003.","journal-title":"J Cardiovasc Electrophysiol"},{"issue":"12","key":"2321_CR19","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1161\/CIRCEP.123.012567","volume":"16","author":"AJ Camm","year":"2023","unstructured":"Camm AJ, Piccini JP, Alings M, et al. Multicenter, phase 2, randomized controlled study of the efficacy and safety of etripamil nasal spray for the acute reduction of rapid ventricular rate in patients with symptomatic atrial fibrillation (ReVeRA-201). Circ Arrhythm Electrophysiol. 2023;16(12):639\u201350.","journal-title":"Circ Arrhythm Electrophysiol"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02321-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-026-02321-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02321-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T06:39:34Z","timestamp":1782196774000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-026-02321-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,2]]},"references-count":19,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["2321"],"URL":"https:\/\/doi.org\/10.1007\/s40265-026-02321-1","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,2]]},"assertion":[{"value":"30 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Michael B. Brown is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}